These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 35441772)

  • 1. The efficacy of botulinum toxin A in the treatment of Raynaud's phenomenon in systemic sclerosis: A randomized self-controlled trial.
    Du W; Zhou M; Zhang C; Sun Q
    Dermatol Ther; 2022 Jul; 35(7):e15529. PubMed ID: 35441772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beneficial effect of botulinum toxin A on Raynaud's phenomenon in Japanese patients with systemic sclerosis: A prospective, case series study.
    Motegi S; Yamada K; Toki S; Uchiyama A; Kubota Y; Nakamura T; Ishikawa O
    J Dermatol; 2016 Jan; 43(1):56-62. PubMed ID: 26173902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful treatment of Raynaud's phenomenon and digital ulcers in systemic sclerosis patients with botulinum toxin B injection: Assessment of peripheral vascular disorder by angiography and dermoscopic image of nail fold capillary.
    Motegi SI; Sekiguchi A; Saito S; Ishibuchi H; Kishi C; Yasuda M; Ishikawa O
    J Dermatol; 2018 Mar; 45(3):349-352. PubMed ID: 29164658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].
    Serri J; Legré R; Veit V; Guardia C; Gay AM
    Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Botulinum Toxin B Injection for Raynaud's Phenomenon and Digital Ulcers in Patients with Systemic Sclerosis.
    Motegi SI; Uehara A; Yamada K; Sekiguchi A; Fujiwara C; Toki S; Date Y; Nakamura T; Ishikawa O
    Acta Derm Venereol; 2017 Jul; 97(7):843-850. PubMed ID: 28358168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Botulinum Toxin in Adults with Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study.
    Senet P; Maillard H; Diot E; Lazareth I; Blaise S; Arnault JP; Pistorius MA; Boulon C; Cogrel O; Warzocha U; Rivière S; Malloizel-Delaunay J; Servettaz A; Sassolas B; Viguier M; Monfort JB; Janique S; Vicaut E;
    Arthritis Rheumatol; 2023 Mar; 75(3):459-467. PubMed ID: 36066501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Therapeutic Efficacy of Botulinum Toxin in Treating Scleroderma-Associated Raynaud's Phenomenon: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
    Bello RJ; Cooney CM; Melamed E; Follmar K; Yenokyan G; Leatherman G; Shah AA; Wigley FM; Hummers LK; Lifchez SD
    Arthritis Rheumatol; 2017 Aug; 69(8):1661-1669. PubMed ID: 28426903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimisation of botulinum toxin type a treatment for the management of Raynaud's phenomenon using a dorsal approach: a prospective case series.
    Dhaliwal K; Griffin MF; Salinas S; Howell K; Denton CP; Butler PEM
    Clin Rheumatol; 2019 Dec; 38(12):3669-3676. PubMed ID: 31482318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Botulinum toxin in the management of primary and secondary Raynaud's phenomenon.
    Ennis D; Ahmad Z; Anderson MA; Johnson SR
    Best Pract Res Clin Rheumatol; 2021 Sep; 35(3):101684. PubMed ID: 33965340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of botulinum toxin type A injection for Raynaud's phenomenon and digital ulcers in patients with systemic sclerosis.
    Jokar MH; Baghbani B; Geraylow KR; Shariati J; Mehrad-Majd H; Mirfeizi Z; Hashemzadeh K
    Reumatologia; 2022; 60(6):392-398. PubMed ID: 36683833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Botulinum Toxin Type A and its Potential Effect on Exacerbated Raynaud's Phenomenon in Hospitalized Scleroderma Patients.
    Seyedmardani SM; Aghdashi MA; Soltani S; Zonouz GK
    Curr Rheumatol Rev; 2022; 18(1):48-57. PubMed ID: 34636314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The novel use of botulinum toxin A for the treatment of Raynaud's phenomenon in the toes.
    Dhaliwal K; Griffin M; Denton CP; Butler PEM
    BMJ Case Rep; 2018 Mar; 2018():. PubMed ID: 29525756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective study of the use of botulinum toxin injections in the treatment of Raynaud's syndrome associated with scleroderma.
    Uppal L; Dhaliwal K; Butler PE
    J Hand Surg Eur Vol; 2014 Oct; 39(8):876-80. PubMed ID: 24369360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted high concentration botulinum toxin A injections in patients with Raynaud's phenomenon: a retrospective single-centre experience.
    Nagarajan M; McArthur P
    Rheumatol Int; 2021 May; 41(5):943-949. PubMed ID: 32447423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 4-week comparison of capillaroscopy changes, healing effect, and cost-effectiveness of botulinum toxin-A vs prostaglandin analog infusion in refractory digital ulcers in systemic sclerosis.
    Shenavandeh S; Sepaskhah M; Dehghani S; Nazarinia M
    Clin Rheumatol; 2022 Jan; 41(1):95-104. PubMed ID: 34471968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [What's new in the management of systemic sclerosis].
    Khelifa M; Guemara R; Iudici M
    Rev Med Suisse; 2023 Mar; 19(818):521-525. PubMed ID: 36920010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Raynaud's phenomenon with botulinum toxin type A.
    Zhang X; Hu Y; Nie Z; Song Y; Pan Y; Liu Y; Jin L
    Neurol Sci; 2015 Jul; 36(7):1225-31. PubMed ID: 25616446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Raynaud's phenomenon.
    Hughes M; Herrick AL
    Best Pract Res Clin Rheumatol; 2016 Feb; 30(1):112-32. PubMed ID: 27421220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Botulinum toxin type A: a treatment option for digital ischemia in patients with Raynaud's phenomenon.
    Fregene A; Ditmars D; Siddiqui A
    J Hand Surg Am; 2009 Mar; 34(3):446-52. PubMed ID: 19258141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OnabotulinumtoxinA for Systemic Sclerosis-associated Raynaud's Phenomenon: A Multi-Institutional Study on Accessibility and Effectiveness.
    Kassamali B; Desai S; Min M; Mazori D; Villa-Ruiz C; Kus K; Cobos G; Merola J; LaChance A; Vleugels R
    J Drugs Dermatol; 2021 Nov; 20(11):1257-1259. PubMed ID: 34784129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.